The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) has entered into a significant five-year strategic research collaboration with GSK. This partnership aims to advance human cellular models of neurodegenerative diseases, particularly focusing on conditions like Alzheimer’s disease. The collaboration seeks to bridge the gap between scientific discovery and the development of new medicines, leveraging human stem cell research, advanced data science tools, and large-scale research systems.
Lon Cardon, president and CEO of JAX, emphasized the importance of this collaboration, stating, “This collaboration is a concrete example of where early-stage biomedical research is heading.” The initiative follows JAX’s recent expansion of its discovery platform through the acquisition of NYSCF. The goal is to create disease-relevant cellular models that allow researchers to investigate the underlying human biology of neurodegenerative diseases and expedite the translation of those findings into potential therapies.
Building Predictive Models for Drug Discovery
By integrating GSK’s extensive knowledge in neurodegeneration, translational science, and drug discovery with JAX-NYSCF’s cutting-edge stem cell technology, the partners aim to produce more predictive models for identifying and prioritizing promising drug candidates. This collaboration is expected to enhance insights into therapeutic discovery for challenging neurodegenerative diseases, leveraging GSK’s established expertise in immunology and inflammation.
Chris Austin, senior vice president and global head of Research Technologies at GSK, noted the potential of this partnership. He stated, “Establishing a translational biology and scientific discovery collaboration with JAX-NYSCF complements the work we are doing at GSK on cellular models of disease.” The collaboration aims to develop an improved understanding of neurodegenerative conditions, ultimately leading to the creation of new medicines tailored to specific patient needs.
This innovative approach reflects a commitment to harnessing the latest advancements in biomedical research. By utilizing patient-derived induced pluripotent stem cell (iPSC) models, the collaboration aspires to more accurately capture the complexity of human biology at scale. The integration of these models will not only facilitate the identification of potential therapies but also help determine which patients are most likely to benefit from these new interventions.
As the collaboration unfolds, the scientific community anticipates breakthroughs that could significantly impact the treatment landscape for neurodegenerative diseases. The partnership underscores the importance of collaboration in addressing some of the most pressing challenges in biomedical research today, with the potential to accelerate progress towards effective therapies for patients in need.
